The majority of the cancer drugs that came on the European market between 2009 and 2013 had no proven effect on either the life expectancy or the quality of life (Davies et al. 2017).

Reference

Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ 2017;359:j4530. doi:10.1136/bmj.j4530.

Similar questions and discussions